Please use this identifier to cite or link to this item:
|Title:||Targeted alpha therapy with Pb-212 or Ac-225: change in RBE from daughter migration|
|Author:||Ackerman, Nicole L.|
Rosales, Liset de la Fuente
Vallis, Katherine A.
Bernal, Mario A.
|Abstract:||Targeted alpha-therapy (TAT) could be delivered early to patients who are at a high-risk for developing brain metastases, targeting the areas of the vasculature where tumor cells are penetrating into the brain. We have utilized a Monte Carlo model representing brain vasculature to calculate physical dose and DNA damage from the a-emitters Ac-225 and Pb-212. The micron-scale dose distributions from all radioactive decay products were modeled in Geant4, including the eV-scale interactions using the Geant4-DNA models. These interactions were then superimposed on an atomic-scale DNA model to estimate strand break yields. In addition to Ac-225 having a higher dose per decay than Pb-212, it also has a double strand break yield per decay that is 4.7 +/- 0.5 times that of Pb-212. However, the efficacy of both nuclides depends on retaining the daughter nuclei at the target location in the brain vasculature. The relative biological effectiveness (RBE) of Ac-225 and Pb-212 are similar when the entire decay chains are included, with maxima of 2.7 +/- 0.6 and 2.5 +/- 0.5 (respectively), and RBE values of about 2 to a depth of 80 mu m. If the initial daughter is lost, the RBE of Pb-212 is completely reduced to 1 or lower and the RBE of Ac-225 is approximately 2 only for the first 40 mu m.|
|Subject:||Dano ao DNA|
Método de Monte Carlo
|Appears in Collections:||IFGW - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.